{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-019976","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.812894+00:00","generated_at":"2026-05-18T05:56:01.680074+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"medium","headline":"Harrow secures exclusive U.S. rights to two ophthalmology biosimilars from Samsung Bioepis","bullets":["Gains exclusive U.S. commercial rights to BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy), FDA-approved biosimilars of Lucentis and Eylea.","Consideration includes one-time upfront payment, net-sales milestone payments, and a share of U.S. net sales (amounts not disclosed).","Transition of commercial rights from Biogen to Samsung expected by end of 2025; Harrow will then assume full commercialization.","U.S. retinal disease treatment market valued at ~$9B; products target Wet AMD, Macular Edema, DME, and Diabetic Retinopathy.","CEO Mark Baum calls the acquisition transformational, reinforcing Harrow's commitment to affordable alternatives in eyecare."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-019976","json":"https://secwatch.observer/filing/0001641172-25-019976.json","markdown":"https://secwatch.observer/filing/0001641172-25-019976.md","text":"https://secwatch.observer/filing/0001641172-25-019976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/0001641172-25-019976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:56:01.680074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}